Biocytogen announces that ADC innovator Tubulis has signed a worldwide exclusive license agreement for a single antibody
Thursday, September 18, 2025
Biocytogen Pharmaceuticals Co., Ltd a global biotechnology company advancing the research and development of novel antibody therapeutics with innovative technologies, today announced that ADC developer Tubulis has acquired an exclusive license for the global development and commercialization of a fully human antibody developed by Biocytogen. This antibody will be incorporated into a novel, proprietary ADC candidate developed by Tubulis. This is part of a previously signed research and option agreement to discover and refine antibody components for the development and commercialization of ADC products based on Biocytogen’s antibody discovery platform.
This announcement is officially valid in the original source language. Translations are provided as a reading aid only and should be compared with the original text, which alone is legally binding.
Contacts
Contacts for Biocytogen
Antibody Assets and Platforms:BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
Source: businesswire.com
